Certain Common Stock of Co-Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 8-JAN-2018.
January 07, 2018
Share
Certain Common Stock of Co-Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 8-JAN-2018. These Common Stock will be under lockup for 180 days starting from 12-JUL-2017 to 8-JAN-2018.
Details:
The executive officers, directors and holders of substantially all of common stock have agreed that they will not offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of any common stock or securities convertible into or exchangeable or exercisable for any common stock, for a period of 180 days from the date of effectiveness of the offering without the prior written consent of WallachBeth Capital, LLC and Network 1 Financial Securities, Inc.
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Companyâs technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the userâs mobile device.
CO-DIAGNOSTICS, INC. 
